Royalty Report: Drugs, Autoimmune, Disease – Collection: 359530

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Autoimmune
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Drug Discovery
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 359530

License Grant
Licensee acquires IMU-838 and IMU-935 from German Licensor.
License Property
IMU-838, targets DHODH, a key enzyme in the intracellular metabolism of immune cells in the body. The IMU-838 program is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (“DHODH”).

IMU-935, is a highly potent and selective inverse agonist of a transcription factor called ROR?t with additional activity on DHODH. IMU-935 program is focused on an inverse agonist of ROR?t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (“ROR?”).

Field of Use
Field of use is for selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis (“RRMS”), ulcerative colitis (“UC”), Crohn’s disease (“CD”) and psoriasis.

IPSCIO Record ID: 7344

License Grant
The Licensee entered into an exclusive License Agreement (with a right to subLicense) with the Licensor, a nonprofit medical research facility, for the rights to novel modulators of sphingosine phosphate receptors, including modulators to the S1P1R.
License Property
The technology Licensed covers RPC1063.

RMS  RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).

RPC1063 for the treatment of UC IBD is comprised of two chronic, autoimmune, GI inflammatory disorders UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.

Field of Use
RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD).

IPSCIO Record ID: 310351

License Grant
Swiss Seller grants to Purchaser an exclusive, perpetual, irrevocable, royalty-bearing, sublicensable, assignable license under the Licensed IP to use the Licensed IP solely to Develop and Commercialize the Product in the Field in the Territory and to manufacture or have manufactured the Product for use in the Field in the Territory.
License Property
Product means (i) Synacthen and Synacthen Depot, and (ii) any product for use in the Field in the Territory containing the Drug Substance (either alone or in combination with other active pharmaceutical ingredients) which is Developed or Commercialized using the Licensed IP. For the sake of clarity, the Parties acknowledge and agree that the Product does not include the tetracosactide product commercialized by Sellers Affiliate as of the Effective Date.

Synacthen is a synthetic melanocortin agonis for certain autoimmune and inflammatory conditions.  The Synacthen transaction leverages our understanding of the different characteristics and biological activity of melanocortin receptor agonists as well as the potential use of melanocortin receptor agonists in the treatment of serious and difficult-to-treat autoimmune and inflammatory disorders.

Synacthen means SYNACTHEN® i.m./i.v. 0.25 mg/mL solution for injection (or other dosage strength and/or form) that includes the Drug Substance as the sole active ingredient.

Synacthen Depot means SYNACTHEN DEPOT® i.m. 1 mg/mL suspension for injection (or other dosage strength and/or form) that includes the Drug Substance as the sole active ingredient.

Drug Substance means the active pharmaceutical ingredient tetracosactide acetate (a synthetic ACTH analogue) contained in the Product having the structure set forth in this Agreement, and all other salt forms of such tetracosactide.

Trademark means the trademark SYNACTHEN (Serial Number 85495963 with filing date December 15, 2011) in the Territory as provided in this agreement, including all goodwill associated therewith.

Licensed IP means any Global Medical Information, Know How, the Trademark, the Domain Names and Information (and any intellectual property rights in the foregoing) in each case that is necessary for the Development and/or Commercialization of Product in the Field in the Territory and in each case that is in existence and owned or controlled by Seller and/or its Affiliates or which Seller and/or its Affiliates have a right to license as of the Effective Date.

Domain Names shall mean synacthen.com.

Global Medical Information shall mean any medical or clinical information, adverse event reports and/or safety information related to the Product and/or the Drug Substance owned or controlled by or on behalf of Seller and/or its Affiliates in the Field, and including but not limited to clinical study reports, pre-clinical data and toxicity data that are in existence on the Effective Date.

Field of Use
Field shall mean all uses in humans for the treatment of serious and difficult-to-treat autoimmune and inflammatory disorders by leveraging the understanding of the different characteristics and biological activity of melanocortin receptor agonists as well as the potential use of melanocortin receptor agonists in the treatment of these disorders.

Synacthen and Synacthen Depot are available in more than forty countries to treat a number of conditions including some rheumatoid diseases, ulcerative colitis, chronic skin conditions not responsive to corticosteroids, Bell's palsy, acute exacerbations in patients suffering from multiple sclerosis and periarteritis nodosa. Synacthen and Synacthen Depot are also used as a diagnostic test for adrenal insufficiency.

Purchaser is a biopharmaceutical company primarily focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.

IPSCIO Record ID: 341530

License Grant
Under the terms of the new arrangement, Belgium Licensee will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe.
License Property
Filgotinib preferential JAK1 inhibitor with a potential best-in-class product profile (Jyseleca). Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA. Filgotinib is a preferential JAK1 inhibitor. Jyseleca® is the brand name for filgotinib
Field of Use
Field of Use is for the treatment of IBD (Inflammatory Bowel Disease), CD (Crohns Disease), UC (Ulcerative Colitis) and potentially other inflammatory diseases such as RA (Rheumatiod arthritus).

Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.

Crohn’s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.

Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).

Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.

Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.

IPSCIO Record ID: 337709

License Grant
The parties agree to commercialize fostamatinib in all potential indications, including chronic ITP and AIHA, in Canada and Israel.
License Property
Fostamatinib has the brand name of Tavlesse (Tavalisse). It is a tablet, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.

ITP means immune thrombocytopenia where the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.

Field of Use
Field of use is for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments and to reduce the destruction of red blood cells in the AIHA disease.

AIHA means autoimmune hemolytic anemia.  It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.

IPSCIO Record ID: 385688

License Grant
Licensor grants under the Licensor Technology, Collaboration Inventions, and all patents claiming Collaboration Inventions, a co-exclusive license, together with Licensor, to develop in accordance with the Development Plan and use Licensed Products in the Asthma Field with respect to U.S. Territory and the European Union, a co-exclusive license, together with Licensor, to import Licensed Products in the Asthma Field into the European Union for such Development purposes, an exclusive license to import, offer for sale and sell Licensed Products in the Asthma Field in the U.S. Territory, and an exclusive license to make Licensed Products in the Asthma Field in the Territory.

For Additional Licenses to Collaboration Inventions, Licensor grants, under the Collaboration Inventions and all patents claiming Collaboration Inventions a co-exclusive license to develop, make, use, import, offer for sale and sell products, other than Licensed Products or Excluded Products, containing antibodies that bind to IL-2R in the Asthma Field in the Territory; and a co-exclusive license to develop, make, use, import, offer for sale, and sell Licensed Products and other products containing antibodies that bind to IL-2R, other than Excluded Products, in Licensee’s Exclusive Field in the Territory.

For the Trademark License, Licensor grants the co-exclusive right and license, together with Licensor to use the Zenapax Trademark solely in connection with the development, use, marketing, promotion, and detailing of Licensed Products in the Asthma Field in the U.S. Territory, the co-exclusive right and license, together with Licensor, to use the Zenapax Trademark solely in connection with the development of Licensed Products in the Asthma Field with respect to the European Union, and the exclusive right and license to use the Zenapax Trademark solely in connection with the offer for sale and sale of Licensed Products in the Asthma Field in the U.S. Territory.

License Property
Licensor currently markets a humanized antibody against the interleukin-2 (IL-2) receptor Daclizumab, under the trademark Zenapax®.

Autoimmune Indications or Al means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active nonpathogenic hepatitis, non-infectious uveitis (Behcets), aplastic anemia, regional nonpathogenic enteritis (including ulcerative colitis, Crohns Disease and inflammatory bowel disease), Kawasakis disease, post-infectious encephalitis, multiple sclerosis, and tropic spastic paraparesis.

Oaclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name Daclizumab by the United States Adopted Names Council. Oaclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.

Licensed Product shall mean any pharmaceutical product having as an active ingredient Oaclizumab.

Zenapax Trademark means the trademark Zenapax®, and all trademark registrations and applications therefor, and all goodwill associated therewith.

Field of Use
Zenapax (daclizumab), a Phase II humanized monoclonal antibody for moderate to severe asthma.   “Asthma Field” means the treatment and/or prevention of asthma or other respiratory diseases.

The Exclusive Field means, with respect to Licensor, Licensors Exclusive Field and, with respect to Licensee, Licensees Exclusive Field.

Licensors Exclusive Field means the Transplant Indications, Notwithstanding the foregoing, upon the first to occur of the Reversion Effective Date or the Put Right Effective Date, the term Licensors Exclusive Field shall have no meaning.

Licensee’s Exclusive Field means the Autoimmune Indications, excluding the Asthma Field, Other Indications and, upon the first to occur of the Reversion Effective Date or the Put Right Effective Date, the Transplant Indications.

IPSCIO Record ID: 391426

License Grant
The Parties are entering into a worldwide collaboration for the joint development and commercialization of Daclizumab for the treatment of asthma and other respiratory diseases.

In the U.S. Territory
— For the Technology License, Licensor grants a co-exclusive license, together with Licensor, under the Licensor Technology, to develop Licensed Products in the Asthma Field with respect to the U.S. Territory and the European Union, in accordance with the Development Plan, and to import and use Licensed Products for such purposes.  The foregoing licenses include the right to perform Development outside the U.S. Territory and European Union in accordance with the Development Plan with respect to any Licensed Product solely in order to obtain Regulatory Approval of such Licensed Product in the Asthma Field in the U.S. Territory or the European Union.
—  Promotion Right, Licensor grants a co-exclusive, together with Licensor, non-transferable right to Promote and Detail Licensed Products in the Asthma Field in the U.S. Territory during the Co-Promotion Term, in accordance with applicable law and the Commercialization Plan.

In the ROW Territory
— For the Technology License, Licensor grants the exclusive, even as to Licensor, license, under the Licensor Technology, to develop Licensed Products in the Asthma Field in the ROW Territory, other than the European Union, to use and import Licensed Products in the Asthma Field in the ROW Territory, other than the European Union, for such Development purposes, offer for sale and sell Licensed Products in the Asthma Field in the ROW Territory, to use and import Licensed Products in the Asthma Field in the ROW Territory for such commercialization purposes; provided, however, that the license granted with respect to the Queen Patents shall be nonexclusive.

For the Trademark License, Licensor grants the exclusive right and license to use the Licensor Trademarks solely in connection with the development, use, marketing, promotion, detailing, offer for sale and sale of Licensed Products in the Asthma Field in the ROW Territory; provided, however, that Licensee’s license shall be co-exclusive, together with Licensor, with respect to Development in the European Union.

For the Commercialization by Licensee in ROW Territory, except as expressly set forth, Licensee shall have sole responsibility and decision-making authority for the marketing, promotion, sale and distribution of the Licensed Product in the Asthma Field in the ROW Territory.

License Property
Licensor has acquired all rights to Zenapax, excluding transplantation indications but with the option to gain such indication rights by 2007.

Licensor Technology includes ownership of the Licensor Inventions, Know-How and Patents.

Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab.

Collaboration Inventions means all inventions that relate to or are useful with antibodies that bind the IL-2 receptor (IL-2R) and are made during the term of this Agreement by employees of Licensee or persons contractually required to assign or license patent rights covering such inventions to Licensee, in the course of performing Licensee’s obligations, or exercising Roche’s rights, under this Agreement.

Autoimmune Indications or Al means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active nonpathogenic hepatitis, non-infectious uveitis (Behcets), aplastic anemia, regional nonpathogenic enteritis (including ulcerative colitis, Crohns Disease and inflammatory bowel disease), Kawasakis disease, post-infectious encephalitis, multiple sclerosis, and tropic spastic paraparesis.

Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name Daclizumab by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.

Zenapax Trademark means the trademark Zenapax®, and all trademark registrations and applications therefor, and all goodwill associated therewith.

Field of Use
The Exclusive Field means, with respect to Licensee, Licensees Exclusive Field and, with respect to Licensee, Licensees Exclusive Field.

Licensors Exclusive Field means the Autoimmune Indications, excluding the Asthma Field.

Licensees Exclusive Field means the Transplant Indications.

IPSCIO Record ID: 269086

License Grant
This exclusive license agreement with Licensee is to commercialize fostamatinib in all indications, including chronic ITP, AIHA, and IgAN, in Europe and Turkey.  Licensee will receive exclusive rights to fostamatinib in human diseases, including chronic immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN).
License Property
Fostamatinib refers to fostamatinib disodium hexahydrate which is an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment (product called TAVALISSE®)

The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Field of Use
Fostamatinib is a medication for the treatment of chronic immune thrombocytopenia.

Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.